. . rmrustration ruled to deny the availability of MDhM for medical use. This decision was influenced not only by media reports sensationalizing its use in the population, but by laboratory studies repordng serotonergic neurotoxicity in animals. Subsequent investigations were also directed a t evaluating neurotoxicity in humans p r e .. ..
have, on careful examination, often c o n h e d flaws in methodology as well as interpretation. One frequently cited study has claimed to have found "central serotonergic dysfunction" in individuals with past use of MDhlA who were admhktered L-tryptophan challenge tests (Price et al.. 1989) . We have discussed elsewhere (Grob et al., 1990 ) that methodological flaws, including lack of baseline measures as well as inadequate screening for other psychotropic drugs that affect serotonergic function, raise questions regarding the signi6cance of these fmdings. This study also failed to mention that their nine subjects who were preselected 5hydroxyindoleacetic acid levels froni a larger group of 31 h e a~y hlDMA users (Doblin, personal communication). producing a sample uith a clear bias for producing results indicative of central serotonergic dysfunction.
Since 1985, when reports first swfaced of serotonergic newotodcity in laboratory animals administered large m o u n t s of hiD\L\ expectations gren7thata flood of patients ulth damaged serotonergic neurotransmitter systems would surface. Such anticipation was in large part fueled by confusion of hlDM.4 uith the opiate analogue l-methyl4-phenyl-l,2.3,6-tetrahydrop~e (MPTP, Beck. 1990 ). which had been demonstrated earlier in the decade to cause severe and irreparable damage ro thedopaminergic %stem. However, the degree to which clinical cases of MDhL4-presumed damage to serotonergic function have been reported has been surprisingly limited. and confounded by associated variables. McCann and Ricaurte (1991) recently reported on two cases of depression fouowing self-adminimation of hiD>t% Given the degree of premorbid psychopathology and prior polysubstance abuse of these subjects, direct "evidence" linking hfDhM to clinically manifest serotonergic deficit syndromes remains uncertain. Another clinical case report OVhitaker-Azmilia and Aronson, 1959) associating hiDhlA use uith two transient anxiety episodes may not have given sufficient attention to the highly adverse setting for the experiences (the New York City subway system). Although hlDhlA is by no means an innocuous dmg, particularly when used by vulnerable and unprepared individuals in uncontrolled setfings, clinical evidence to date e x a n w g the degree of risk pertinent to the low dose. highly controlled therapeutic MDhL4 treatment model remains Limited. In suppon of this. legal h I D M psychotherapy research has been under way in Switzerland since 1988 without reports of adverse newopsywere among those with the lowest ~e r e b r &~i n a l fluid chiauk squelae. Concern has also been raised over what has been tremely rare" (Peroutka. 19S9). The oldy National I~lsti-lute of Drug Abuse-funded study inlo the hllnlan us(? of hlDhlA, as well as rhree other studies of l~onmdical XIDhlA use, one i l l the litlited Srntes and one ~;~c h in the Netherlands and Australia, provide addiliollal evidence suggestive of a relatively low abuse potential (Beck et al., 1989 , Korfet al.. 1991 Siegel, I!)SG; Solowij and Lee. 1991) . In fact, hlDhZA appears to be rather unique among the socalled recreational dntgs, in that most indixiduals who have raken the drug report a relative disinclination, rather than a waling, lo take the drug repeatedly. Repons of abuse have been particularly uncommon among those who have used hlDhZA for therapeutic or spiritual purposes (Beck. 1990 ; Watson and Beck, 1991) . Funher elucidation of the term neurotosicity as it applies to the serotonergic system is also necessary. E~idence showing actual regeneration of neuronal Lerminals presumed permanently destroyed by massive amounts of MDhZA in laboratory aninials (Battaglia et al., 1987) needs to be considered. Xe\r findings examining the effect of the highly potent serotonergic neurotoxin 5,i-dihydroxynyptamine may also be relevant. 5, i-Dihydruxytryptamine appears to reactivate dormant developmental signals in the brain which encourage sprouting of serotonergic fibers as well as stimulation of an asmocytic grow-& factor. To activate these meehanisms, which are postulated to have a role in healthy regeneration and treatment of the aged brain, serotonergic neurons must fvst be "damaged or blocked (Azmitia and Whitaker-Azmitia. 1991). Such findings indicate that conclusions about the meaning of hlDhZAinduced "neurotoxicity" are premature.
Should MDhW be the subject of clinical research?
The recreational use of MDMA, as nell as initial concerns about m c t u r a l and functional brain damage, has up to now prevented clinical investigators from gathering data in humans about hlDhKs risk to benefil ratio. We believe that a thorough yet dLspassionate review of the existing data suggests that the experimental use of hlD.MA in Inltllans can t,r justified. IL is necessary to draw a clear distinctic>t~ t,ctween uncontrolled use of hIDhI.4 for n o t~~l~e r a l ) n~t i c purposes and prr~posals for sanctioned alq~licaliolt of \IDMA in treatment settings, particularly for casrs refractory to convenrional Lherapies. We nlust now begin to a s k open-minded questiol~s that n1nF porentinll. )ield new and innoxlti1.e treatment modaliries, eve11 if such approaches include novel psychoactive drugs such as hIU31.4.
